As the years pass, our bodies take on many changes. Some we can control and others, like Osteoarthritis (OA), are a little more out of our hands – but that doesn’t mean you have to let it control you! In this article, we will explore the connection between aging and OA, what causes it, how to manage your symptoms effectively so that you can age gracefully with an active lifestyle. So if you’re ready to get proactive about your health as you age and learn how to best manage the effects of osteoarthritis in your life, then stay tuned for some exciting tips. [Read more…]
Pricing Of Approved Cell Therapy Products
Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T therapy in the United States. Novartis announced that its genetically modified autologous (“self-derived”) immunocellular therapy, Kymriah, will cost $475,000 per treatment course. Shortly thereafter, Kite Pharma announced the approval of its CAR-T therapy, Yescarta, in the U.S. with a list price of $373,000. While these prices are expensive, they are far from trendsetting.
Cell Therapy Pricing and Products
In this article:
StemSight Bolsters Leadership Team and Adds Extensive Experience in Cell Therapy Commercialization with Key Hire
In the field of groundbreaking regenerative medicine, StemSight’s aim to cure blindness takes a major leap forward with the strategic appointment of Dr Ross Macdonald as Chief Commercial Officer.
Tampere, Finland, 21.11.23 — StemSight Oy, the leading deep tech company dedicated to eliminating corneal blindness through stem cell technology, proudly announces the appointment of Dr Ross Macdonald to advance the Company’s commercial strategy. With over three decades of pharmaceutical and biopharma industry expertise, Macdonald’s inclusion in StemSight’s team brings a new breadth of experience to the Company. [Read more…]
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide Wnt3a alternative peptide (β-catenin pathway agonist)
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “Wnt3a alternative peptide (β-catenin pathway agonist)” which has equivalent function to recombinant Wnt3a as well as GSK-3β inhibitors, such as CHIR99021(CHIR)). This product will be available in the middle of November 2023. [Read more…]
VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600M Japanese yen ($4M USD) through Third-Party Allotment
Cumulative Funds Raised Amount to Approximately 1.7 billion yen (Approximately $11.3 million USD)
KOBE, Japan — VCCT Inc. (President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new shares to Sysmex Corporation (President: Kaoru Asano), DAI-DAN CO., LTD. (Representative Director, President: Ichiro Fujisawa), and YASKAWA Electric Corporation (Representative Director, President: Masahiro Ogawa). VCCT will continue to accelerate the development of retinal regenerative medicine together with these partners. [Read more…]
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 334
- Next Page »